Variable responses to rituximab treatment in neuromyelitis optica (Devic’s disease)
- 10 August 2007
- journal article
- case report
- Published by Springer Nature in Neurological Sciences
- Vol. 28 (4), 209-211
- https://doi.org/10.1007/s10072-007-0823-z
Abstract
We have described two cases of Devic's disease patients treated with rituximab with different outcomes. The results indicate that there may be early unresponsiveness in very aggressive cases. Well designed clinical trials are needed to assess treatment effects in such a rare disease.Keywords
This publication has 10 references indexed in Scilit:
- Identification of new serum autoantibodies in neuromyelitis optica using protein microarraysNeurology, 2006
- Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic Disease)Archives of Neurology, 2006
- Revised diagnostic criteria for neuromyelitis opticaNeurology, 2006
- IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channelThe Journal of Experimental Medicine, 2005
- Neuromyelitis opticaCurrent Treatment Options in Neurology, 2005
- An open label study of the effects of rituximab in neuromyelitis opticaNeurology, 2005
- A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosisThe Lancet, 2004
- Clinical characteristics, course and prognosis of relapsing Devic?s Neuromyelitis OpticaZeitschrift für Neurologie, 2004
- A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis opticaBrain, 2002
- The clinical course of neuromyelitis optica (Devic’s syndrome)Neurology, 1999